Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00619736 | Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male Subjects | PHASE1 | COMPLETED | 56 | — | — | Mar 1, 2008 | Sep 1, 2008 | Jan 30, 2009 | - | — |
| NCT00633048 | Study Evaluating the Safety and Tolerability of NSA-789 | PHASE1 | COMPLETED | 64 | — | — | Mar 1, 2008 | May 1, 2008 | Feb 17, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| NSA-789 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NSA-789 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: * Men aged 20 to 45 years inclusive at screening. * Healthy as determined by the investigator on the basis of screening evaluations. Exclusion Criteria: * Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hemat...